[Revised March 17, 2026]

Executive Summary

Specialty pharmacy refers to the specialized sector of pharmacy practice devoted to dispensing and managing specialty medications – typically high-cost, high-complexity drugs used to treat serious, chronic, or rare health conditions. In contrast to traditional retail pharmacies, specialty pharmacies provide “high-touch” services including extensive patient education, clinical support, and care coordination for conditions such as cancer, hepatitis C, multiple sclerosis (MS), HIV/AIDS, organ transplant, cystic fibrosis, and hemophilia (^[1]) (^[2]). These specialty therapies often require special handling (for example, refrigeration or home injection training) and close monitoring (^[3]) (^[4]). As a result, specialty pharmacies are accredited and staffed with specially trained clinicians to ensure medication adherence and optimal outcomes for patients with complex regimens (^[5]) (^[4]).

The specialty pharmacy market has grown rapidly over the past two decades, driven by an expanding pipeline of biologic and targeted therapies. Where specialty drugs once comprised only a small fraction of prescriptions, they now consume the majority of healthcare drug spending. Specialty medications accounted for only about 27% of U.S. drug spending in 2010, but that figure has now reached 54% as of 2024 — meaning specialty drugs now cost more than all traditional medications combined (^[6]). The U.S. specialty drug market grew from $92.5 billion in 2023 to $129.2 billion in 2024 (^[7]), while per-member specialty drug costs increased from $1,333 to $1,641 in 2024 (^[8]). Specialty drugs still make up only ~2% of prescription volume but represent over half of all spending. The explosive growth of GLP-1 weight-loss and diabetes drugs has added a major new spending category, with weight management medications accounting for 46.8% of the total increase in drug spending in 2024 (^[9]).

Specialty pharmacies do more than dispense medications – they provide intensive case management that can improve patient outcomes. For example, MS patients enrolled in specialty pharmacy programs have been shown to have significantly fewer relapses than those using standard community pharmacies (^[10]). Hepatitis C patients using a specialty pharmacy achieved higher adherence and much higher cure rates than those using retail outlets (^[11]). Even integrated health-system specialty pharmacies (IHSSPs) within hospital systems have demonstrated slightly higher adherence rates and cure rates for HCV compared to external pharmacies (^[12]). These improvements are attributed to personalized counseling, frequent follow-up, and support such as help navigating insurance and financial assistance (^[13]).

Despite the clinical benefits, specialty pharmacy raises complex economic and policy issues. High specialty–drug prices and complex benefit designs have attracted scrutiny of middlemen (^[14]) and regulators. Recent investigations highlighted that large PBMs can make multi-billion-dollar markups on specialty medications, and that vertical integration (e.g. PBMs owning specialty pharmacies) spurs debate about conflicts of interest (^[15]). The FTC's landmark February 2026 settlement with Express Scripts — requiring elimination of spread pricing and delinking PBM compensation from drug list prices — signals a major shift in PBM regulation (^[16]). Meanwhile, employers and insurers face mounting costs: one survey found 51% of major employers plan to cut benefits in 2026 due to rising specialty drug and weight-loss drug costs. At the same time, innovative models are emerging (such as pharmacies embedded in specialty clinics) to streamline treatment access. Looking ahead, specialty pharmacy will have to adapt to new frontiers like gene and cell therapies and digital health tools. This report provides an in-depth examination of specialty pharmacy, covering its history, current state, service models, economic impact, and future directions, drawing on extensive data, case studies, and expert analysis.

Introduction and Background

The modern specialty pharmacy industry evolved in response to novel, high-cost treatments that exceeded the capabilities of traditional retail pharmacies. Historically, retail drugstores focused on high-volume, low-complexity medications (e.g. antibiotics, blood pressure pills, OTC medicines) for common conditions (^[17]) (^[1]). By contrast, specialty medications began to emerge in the 1990s as treatments for complex chronic and rare diseases, such as injectable therapies for rheumatoid arthritis or interferons for multiple sclerosis (^[18]) (^[1]). These drugs often have a small patient population but a very high per-unit cost. Specialty pharmacy originated as a niche service, initially concentrating on a handful of conditions like HIV and transplant medicine, but it quickly expanded as more biotech products reached the market.During its early years, specialty pharmacy was a grassroots effort, exemplified by companies like Stadtlanders Pharmacy (founded in 1992) which focused on HIV and other complex treatments (^[19]). The model distinguished itself by targeting the small number of patients with high-cost regimens, rather than trying to capture mass-market volume like chain drugstores (^[18]). Industry veterans note the adage: “1 percent of the population, 30 percent of the drug costs” – specialty medications affecting a small patient group can drive a large portion of drug spending (^[20]). Over time, the specialty drug pipeline exploded; less than 30 products were considered “specialty” in the mid-1990s, whereas today hundreds of such medications exist, and projections once estimated over 400 by the early 2020s (^[21]). Broadening indications (e.g. new uses for cystic fibrosis or hepatitis C drugs) and the aging population have further amplified demand.

As specialty drugs multiplied, so did specialized pharmacies and services. These pharmacies typically require accreditation by quality bodies (such as URAC or The Joint Commission (^[5])) and focus on individualized patient care. They often dispense medications via mail-order or dedicated infusion centers, and they employ processes to manage cold-chain logistics, insurance authorization, and ongoing follow-up (^[3]) (^[4]). Unlike retail pharmacists who commonly do point-of-sale counseling, specialty pharmacists engage patients over time – for example, training patients on self-injection techniques or coordinating with caregivers. Specialty pharmacies emerged within community settings (such as within mail-order networks of PBMs) and within health systems (e.g. hospital-based specialty clinics) to ensure accessibility.

Specialty drugs themselves are not officially defined by FDA outside of “designated specialty drugs” for government purchasing, but in practice they share characteristics: high prices, often biologic origin, complex administration (shots, infusions, or strict cold-chain requirements), and the need for intensive clinical management (^[21]) (^[4]). For example, intravenous immunoglobulins for autoimmune disorders cost tens of thousands per patient per year and require infusion setups; sofosbuvir-based regimens for hepatitis C can cost $100,000+ for a multi-week cure; biologics for rheumatoid arthritis (e.g. anti-TNF agents) cost many thousands per month; and gene therapies like CAR-T may exceed $500,000 per course. Table 1 (below) summarizes illustrative disease areas and therapy examples that fall under the specialty category, highlighting their complexity and cost. Because of these attributes, specialty medications often use limited distribution networks (LDNs), where manufacturers restrict which pharmacies can dispense the product. LDNs can assure proper handling but may also impede access if the necessary specialty outlet is not readily available (^[15]) (^[22]).

The key distinction between specialty and retail pharmacy is summarized below (Table 2). Specialty pharmacies focus on complex chronic or rare therapies and provide extra services (adherence support, insurance coordination, financial assistance), whereas retail pharmacies handle high-volume routine prescriptions with limited clinical follow-up (^[2]) (^[1]). This model has become increasingly important as specialty medications now represent a large and growing fraction of overall drug spending (^[24]) (^[25]). Notably, specialty pharmacy practice is governed by industry standards: for example, the National Association of Specialty Pharmacy (NASP) officially defines specialty pharmacies as accredited entities that dispense complex therapies for serious conditions (^[5]) (^[2]).

Table 2: Comparison of retail vs specialty pharmacy characteristics (^[5]) (^[2]).

Historical Development and Industry Evolution

Specialty pharmacy grew quietly at first but became impossible to ignore as drug spending shifted. In the early 2000s, specialty pharmacies were niche, servicing conditions like HIV, MS, transplant medicine and growth disorders. However, by the late 2000s and 2010s, spending on specialty therapies skyrocketed. An early industry commentator noted that from 2006 to 2010 specialty spending was projected to jump from 19% to 26% of total drug spend, potentially reaching $100 billion annually by 2010 (^[27]). Rapid uptake of biologics and a steady pipeline of novel agents meant that specialty pharmacy became a critical focus for payers. The same analysis warned that if the trend persisted, specialty drugs could rise to 44% of health plan drug spending by 2030 (^[28]). Indeed, actual data eventually validated this pattern: by the late 2010s, specialty medications were nearly half of all drug expenditures (^[29]).

Several market forces drove this evolution. High research productivity in biologics translated into more approved specialty drugs. Patent cliffs on many blockbusters left pharmaceutical pipelines relying on specialty (complex) drugs to sustain growth. Meanwhile, health insurers and employer-sponsored plans instituted specialty pharmacy management programs to keep tight control on these costs, often requiring patients to fill certain medications through designated specialty channels. Major pharmacy benefit managers developed in-house specialty pharmacies or partnered with existing ones to capture the margins on these expensive prescriptions. The “specialty pharmacy” concept also aligned with the rise of case management and disease-management programs in managed care – i.e., the industry saw an opportunity to blend clinical services with distribution to improve outcomes and trim waste.

By the 2010s, the specialty pharmacy sector saw consolidation and vertical integration. Retail giants and PBMs made targeted acquisitions: for example, CVS (a chain pharmacy) acquired a specialty mail-order pharmacy (Caremark’s specialty), Cigna (a health insurer with PBM) acquired Diplomat Pharmacy in 2020, and Walgreens (through its DME and pharmacy arms) invested heavily in Shield Health Solutions, a hospital-focused specialty pharmacy (see below). Notable specialty pharmacy chains like Accredo and CuraScript were established or expanded. Independent and regional specialty pharmacies also grew. Industry associations formed (e.g. NASP in 2013) to address the unique practices and regulations in specialty pharmacy, including defining what the term means (^[5]).

Today’s specialty pharmacy industry is highly dynamic. It intersects with various stakeholders: pharmaceutical manufacturers increasingly rely on specialty pharmacies (and LDNs) to dispense their new products; health plans view specialty pharmacies as vehicles to manage adherence and utilization; patients depend on specialty pharmacies (sometimes the only feasible means) to obtain life-improving but expensive therapies; and investors see it as a growing market — as evidenced by recent IPOs and funding rounds. For instance, Guardian Pharmacy Services began gearing up for a U.S. IPO with massive valuation expectations in 2024, reflecting confidence in specialty’s profitability.

Below we explore the current practices, market dynamics, and real-world impacts of specialty pharmacy in depth.

The Role and Services of Specialty Pharmacies

Patient Support and Clinical Services

A hallmark of specialty pharmacy is intensive patient support. Unlike community pharmacists who may only briefly counsel patients, specialty pharmacists develop ongoing relationships. They often serve fewer patients but provide more resources per patient, including:

• Education and Training: Assisting with self-injection or infusion techniques. For example, a specialty pharmacy might demonstrate to a patient how to use an autoinjector pen for arthritis medication, or coach a caregiver on saline flushing for a chemotherapy port.

• Adherence Monitoring: Regular follow-ups (via phone or telehealth) to ensure patients take medications correctly. Specialty programs track progress, refill prescriptions proactively, and intervene if doses are missed, since missing a dose of, say, an MS therapy or an HIV regimen can significantly harm outcomes.

• Side-Effect Management: Nurses or pharmacists specializing in the disease area check on tolerability. If patients report side effects, the specialty pharmacy can liaise with the prescriber to adjust therapy or add supportive meds.

• Prior Authorization and Insurance Navigation: Specialty medications often require complex insurance approvals. Specialty pharmacists (or dedicated liaisons) complete paperwork and appeals, and often get patients enrolled in patient assistance or subsidy programs to alleviate high copays.

• Coordinated Care: They communicate with multiple providers (e.g. oncologist, rheumatologist, PCP) so that medication plans align with overall care. For chronic conditions, these pharmacies may present data to providers on patient’s adherence and outcomes, integrating with the care team.

These services have measurable effects. Research has shown that patients managed through specialty pharmacies have higher adherence rates. For example, an Express Scripts analysis found hepatitis C patients using a dedicated specialty pharmacy were 60% more likely to achieve optimal adherence than those filling at retail pharmacies (^[11]). A specialty pharmacy program for MS patients showed significantly lower relapse rates versus community pharmacy care (^[30]). A university specialty pharmacy with integrated patient management achieved nearly 100% adherence in HCV patients vs 97% at external pharmacies (^[12]). In short, specialty pharmacies deliver comprehensive “medication management” that can improve outcomes in diseases where medication error or nonadherence undermine therapy.

At the same time, specialty pharmacies invest in technology and data analytics. Many have homegrown or vendor platforms to track specialty medication distribution, automate refill reminders, and flag adherence red-flag issues. Some are integrating telehealth and digital coaching tools. Because of these resources, modern specialty pharmacies often measure clinical outcomes (e.g., viral suppression in HCV, time to relapse in MS) and report improvements due to their services, reinforcing their value proposition to payers and providers.

Clinical Outcomes: Evidence from Studies and Case Examples

Real-world data supports specialty pharmacy benefits. We highlight a few notable case examples:

• Multiple Sclerosis (MS): A retrospective cohort study of 1,731 MS patients (2006–2009) compared those receiving specialty pharmacy care vs usual community pharmacy care (^[23]) (^[30]). The specialty pharmacy group had a lower annual relapse rate (0.3 vs 0.4) and a 18–27% lower hazard of first relapse, even after adjusting for factors (^[30]). This suggests that the support and monitoring by specialty pharmacists helped keep patients on therapy and reduced exacerbations. MS drugs are extremely costly and delicate (refrigerated interferons, infusion therapies), so the specialized handling and counseling likely contributed to these improved outcomes.

• Hepatitis C (HCV): Two studies demonstrate specialty pharmacy impact in HCV. First, Express Scripts found that HCV patients who used only a specialty pharmacy achieved optimal adherence 60% more often than those going to retail (^[11]). The study reported roughly 54% of specialty patients vs 41% of retail patients maintained ≥80% adherence; correspondingly, specialty users had 60% higher odds of sustaining a virologic response (cure) (^[13]). Second, an integrated health system’s new specialty pharmacy service for HCV also showed high success. In this URMC study, 93% of patients using the system’s specialty pharmacy achieved SVR, compared with 89% using outside pharmacies (a non-significant trend) (^[12]). Importantly, adherence was 100% in the specialized program versus 97% outside (statistically significant) (^[12]), highlighting that enrolling patients in an in-network specialty program can eliminate lapses in long, multi-month regimens.

• Oncology and Rare Disease: While controlled trials are rarer, specialty pharmacy involvement in cancer care has been linked to reduced hospitalizations and better chemotherapy management. For bone marrow transplant patients, for instance, having a specialty pharmacist on the care team reduced medication errors and improved immunosuppressant blood level control (case report data). Similarly, specialty pharmacies that manage oral oncolytic agents have shown lower abandonment rates (when a patient never starts a prescribed therapy) than historical benchmarks, thanks to copay support.

• Pharmacy-Led Coordination: An innovative example is House Rx, a startup created in partnership with specialty clinics (especially oncology). House Rx embeds pharmacists or trains clinic staff to dispense drugs on-site, streamlining care. Its founders note that current practice — where insurers often route specialty drugs to external pharmacies — causes delays and extra administrative work. By contrast, House Rx’s model keeps prescribing and dispensing under one roof. In early descriptions, the company reported anecdotal improvements in clinic efficiency and patient satisfaction. Although long-term outcome data is not yet public, this model illustrates a push to bring specialty pharmacy even closer to provider settings.

These examples underscore specialty pharmacies’ “value add” in the treatment of complex diseases. The combination of clinical services and oversight can translate to fewer relapses, higher cure rates, and potentially lower total medical costs (e.g. by preventing hospitalizations for disease flares). Specialty pharmacists often track and document such outcomes, which in turn supports negotiations with health plans and justifies investment in specialty care programs.

Challenges of Limited Distribution and Access

One complexity in specialty pharmacy is the Limited Distribution Network (LDN). Manufacturers of certain specialty drugs restrict dispensing to selected pharmacies; sometimes only one or a few specialty pharmacies are allowed to handle a drug (especially new or controlled therapies). While LDNs help maintain drug integrity and allow tight monitoring, they can create barriers. Providers report that navigating LDNs is burdensome: prescriptions must be sent to specific, sometimes unfamiliar pharmacies, which can delay treatment start (^[15]) (^[22]). For example, if a patient’s usual health-system pharmacy is not in the drug’s network, the prescription must be transferred out, causing friction and potential gaps.

These restrictions have prompted some health systems to establish their own in-house specialty pharmacies (IHSSPs) to capture LDN-covered drugs. An IHSSP can negotiate inclusion in LDNs, allowing patients to continue greater continuity of care. As one recent qualitative study notes, providers appreciate IHSSPs because they “enable providers to better focus on clinical care, streamline the patient’s access to medication, and provide essential financial assistance support that allow for confident specialty medication prescribing” (^[31]), effectively mitigating some LDN drawbacks. Nonetheless, LDNs remain a pain point: they can fragment patient care and create clinic workload (e.g. nursing time spent finding the right pharmacy) (^[22]). The net effect is that specialty pharmacies often have to collaborate closely with manufacturer programs and patient assistance networks to manage access under these constraints.

Economic and Market Analysis

Market Size and Growth

The specialty pharmacy market is now a major component of the drug distribution sector. The U.S. specialty drug market grew from $92.5 billion in 2023 to $129.2 billion in 2024, and is projected to continue its rapid expansion through the end of the decade (^[7]). The total U.S. drug market at net prices grew 11.4% in 2024 — a $50 billion increase to $487 billion in aggregate spending — with specialty drugs accounting for the lion’s share of that growth (^[32]). By disease area, oncology drugs make up the greatest share of specialty spending at 47.1%, followed by bleeding/blood disorders (13.6%) and inflammatory conditions (8.1%).

In terms of composition, North America leads the specialty pharmacy sector due to its advanced healthcare infrastructure and per-capita drug spending. Other markets (Europe, Asia) are smaller but growing as novel therapies roll out worldwide.

Here in the U.S., specialty pharmacy spending has been increasing even faster than overall medication spending. Per-member specialty drug costs increased from $1,333 in 2023 to $1,641 in 2024, though the growth rate moderated to 9.6% on a gross cost basis (down from 14.4% in 2023), driven partly by biosimilar adoption (^[8]). Notably, a rising share of the population now receives specialty therapies: traditionally only about 1% of patients used specialty drugs, but that number has climbed to over 5% as of recent years (^[33]). This means payers must manage a larger cohort of patients on these expensive regimens. The top categories driving specialty costs remain inflammatory disorders, oncology, and multiple sclerosis, with some of the very highest expenditures in transplant medicine and rare disease areas. The explosive growth of GLP-1 weight-loss and diabetes drugs has added a major new spending category: weight management medications accounted for 46.8% of the total increase in drug spending in 2024, with GLP-1 prescriptions growing 38% annually (^[9]).

Spending Share and Cost Trends

Even as specialty drugs comprise a small fraction of prescriptions, they represent an outsized — and growing — portion of spending. According to IQVIA, specialty medicines now account for 54% of total U.S. drug spending, up from 49% in 2018 and just 27% in 2010 (^[6]). This milestone means specialty drugs have definitively crossed the halfway mark, consuming more than all traditional medications combined. Within the retail and mail-order channel, specialty products (only ~2% of volume) account for roughly 40% of total spend, while in the institutional (e.g. hospital) channel, specialty items drive about 60% of spending (^[25]). This clearly illustrates the high per-unit costs of these therapies.

Underlying factors for cost growth include new launches, limited competition, and the explosive growth of GLP-1 therapies. Many specialty drugs are biologics or complex small molecules with patent protection, so prices often remain high. Even after generics or biosimilars appear, discounts can be modest — though biosimilar adoption is beginning to have measurable impact (the PSG Artemetrx report noted that biosimilar competition contributed to the moderation of specialty trend growth in 2024). The GLP-1 category has become a major spending driver: Ozempic alone reached $26.4 billion in annual spending, while Mounjaro hit $12.4 billion and Wegovy $7 billion (^[34]). In Medicaid, GLP-1 gross spending increased ninefold from ~$1 billion in 2019 to ~$9 billion in 2024 (^[35]).

The sustained growth underscores that payers and plan sponsors must constantly adjust strategies. In 2024, the three largest specialty pharmacies (CVS, Cigna/Express Scripts, Optum) accounted for two-thirds of all prescription revenues (^[36]), reflecting the continued consolidation of specialty dispensing among major PBM-owned entities.

Major Players and Business Models

The specialty pharmacy landscape consists of a mix of industry segments:

• PBM-owned Specialty Pharmacies: CVS Caremark (with Sav-Rx), Express Scripts (private/mail-order), Cigna’s Diplomat, OptumRx (UnitedHealth) all operate large specialty mail-order pharmacies. These chain entities bundle with the PBM or insurer to capture specialty margins. For example, CVS Health acquired Coram (home infusion) and the above specialty hubs as part of its care delivery division.

• Retail Chain Specialty Divisions: Walgreens operates Shields Health Solutions (hospital specialty) and has a national specialty pharmacy service. Kroger and Walmart have smaller specialty segments, often fulfilling through mail or referral.

• Independent Specialty Pharmacies: Numerous regional and national chains (e.g. Navigators, SpaciousRx, Banner Specialty) focus exclusively on specialty. Some, like Biologics (acquired by Walgreens), catered to niche areas. Many independent shops emerged by acquiring chains or starting mail-order services. These firms often contract with specific insurers or work directly with manufacturers’ patient assistance programs.

• Health-System Specialty Pharmacies: Hospitals and IDNs increasingly open their own pharmacies for specialist treatments. For example, Kaiser Permanente runs a sophisticated mail-order specialty program entirely for its members. University health centers or integrated systems (like Mayo, Cleveland Clinic) sign up as specialty providers to ensure patient retention. These typically handle meds for their employed doctors’ patients, and they emphasize care coordination and profitability retention within the system.

• Manufacturer-Sponsored/Contract Pharmacies: Some pharmaceutical companies arrange specialty drug distribution through preferred pharmacies under limited distribution agreements, sometimes even owning the pharmacy (such as some distribution hubs). These networks are not “pharmacies” per se to the public, but they gate access to certain drugs.

These players often compete and collaborate. For instance, many specialty drugs end up on multiple pharmacies’ formularies, and payers maintain lists of approved specialty networks. However, exclusivity clauses exist. Competition can also be regional: hospitals might steer patients to their own pharmacy, while a PBM push patients to its mail-order affiliate.

Major corporations have invested heavily in specialty pharmacy, and the landscape has shifted dramatically in 2025–2026. Walgreens’ trajectory exemplifies this: in 2021 it paid $970 million to raise its stake in Shields Health Solutions from 23% to 71%, and by 2022 spent another ~$1.37 billion for full ownership (^[37]) (^[38]). However, in August 2025, Sycamore Partners acquired Walgreens for $10 billion, taking the company private and subsequently splitting it into five standalone companies: Walgreens, The Boots Group, Shields Health Solutions, CareCentrix, and VillageMD (^[39]). Shields became an independent entity under CEO Michael Ham, with financing from HPS Investment Partners, Goldman Sachs, and J.P. Morgan (^[40]). Meanwhile, Walgreens has been aggressively closing stores — over 500 of 1,200 targeted locations shuttered by early 2026 — and cutting corporate jobs as part of its restructuring. These moves reflect both the value and the volatility of specialty pharmacy assets in the current market.

Elsewhere, Mark Cuban’s Cost Plus Drugs has expanded into specialty drugs and biosimilars, criticizing PBMs for artificially categorizing drugs as "specialty" to charge higher prices. Cost Plus built a 22,000 sq ft compounding pharmacy in Dallas for sterile injectables and became the first pharmacy integrated into the Rightway PBM network (^[41]). Amazon Pharmacy is expanding same-day delivery to nearly 4,500 U.S. cities by end of 2026 but has limited specialty pharmacy capabilities, partnering with Optum Specialty Pharmacy for most complex medications (^[42]).

Economics: Payers, PBMs, and Markups

Specialty pharmacy’s economics are complex. In many health plans, specialty prescriptions are packaged into the pharmacy benefit, but due to their importance, PBMs often carve out or carve in these services. The PBM model typically involves per-prescription fees plus an opportunity for spread or rebates. In recent investigations, PBMs were accused of profiting substantially on specialty generics. For example, an FTC report revealed that the three largest PBMs (CVS Caremark, Express Scripts, OptumRx) collectively made over $7.3 billion marking up specialty generic cancer drugs over a two-year period (^[43]). This investigation culminated in a landmark FTC settlement with Express Scripts in February 2026, requiring the PBM to eliminate spread pricing, delink compensation from drug list prices, and reshore its group purchasing organization (Ascent) from Switzerland to the U.S. — bringing over $750 billion in purchasing activity back onshore. The settlement is expected to lower patient costs by up to $7 billion over 10 years (^[16]). Cases against CVS Caremark and OptumRx remain pending.

Meanwhile, insurers and employers are sensitive to specialty spend. Labor union and employer surveys indicate that rising specialty drug costs – including new costly weight-loss GLP-1 therapies – are causing many to consider benefit cuts or new management programs (for example, 51% of large employers planned to pare benefits due to these drivers in a 2025 survey (^[44])). Within Medicare, the Inflation Reduction Act’s $2,000 out-of-pocket cap took full effect on January 1, 2025, benefiting approximately 11 million Part D enrollees with average savings of about $600 per year. Enrollees can now spread costs through a Medicare Prescription Payment Plan with equal monthly payments. For 2026, the cap was inflation-adjusted to $2,100 (^[45]). Additionally, the IRA’s Medicare Drug Price Negotiation Program delivered negotiated prices for the first 10 Part D drugs effective January 2026, with 15 more drugs selected for negotiation in 2027 (^[46]).

At the same time, specialty pharmacies face thin margins on each prescription because prices are high but competition is often intense. Large chain specialty pharmacies may negotiate rebates or fees from manufacturers for exclusivity or performance (which retail pharmacies typically cannot secure). The specialty pharmacy’s business model thus relies on high fill volume within its channel plus the extra services it provides (sometimes to justify higher dispensing fees). Many specialty pharmacies note that a single patient may require weekly shipments over many months, meaning lifetime revenues per patient can be substantial, allowing for covering the costs of oversight.

In summary, specialty pharmacy sits at the nexus of high drug costs, payer policies, and patient advocacy. Its rapid growth has changed pharmacy benefits management and promoted a new class of pharmacy service.

Case Studies and Real-World Programs

To illustrate specialty pharmacy in practice, we examine several real-world cases:

House Rx – Integrating Pharmacy in Clinics

House Rx is a startup launched in partnership with oncology clinics to embed pharmacy services directly at the point of care. Its founders observed that specialty medications present unique challenges: insurers and PBMs often require prescriptions be filled externally, delaying treatment and complicating communication with providers. Under the House Rx model, pharmacists (or trained clinic staff) work inside the clinic. They verify prescriptions on the spot, expedite prior authorizations, and can dispense or order the specialty drug immediately. House Rx also assigns a remote pharmacist to audit and verify each regimen. By charging a per-provider subscription fee (initially in Medicare Advantage), House Rx aims to show that faster coordination and potentially improved adherence will yield cost savings. As one analyst noted, ”It's a complementary skillset” as doctors and pharmacists collaborate directly to serve patients. This model highlights a growing trend: specialty pharmacy functions are moving closer to patients and prescribers, rather than functioning exclusively as consumer mail-order.

Hospitals and Health Systems – Shields Health and IHSSP Models

Shields Health Solutions exemplifies pharmacy-hospital collaboration. Shields partners with hospitals to help them establish their own specialty pharmacies, enabling hospitals to manage high-cost therapies (oncology, HIV, etc.) while sharing revenue. Walgreens purchased Shields (first a 71% stake in 2021, then full ownership in 2022) for roughly $2.3 billion (^[37]) (^[38]). After Sycamore Partners’ 2025 acquisition of Walgreens, Shields was spun off as a standalone company — a move that underscores the enduring value of hospital-based specialty pharmacy services. The Shields model continues to demonstrate that health systems and pharmacy partners see mutual incentives in specialty: hospitals want to keep revenues and ensure patient access, while specialty operators can lock in patient volume through embedded clinical workflows.

Other health systems independently have launched future-looking specialty pharmacies. For instance, Kaiser Permanente’s health plans integrate their own pharmacies so members get seamless drug delivery for specialty treatments. Academic centers often publicize that having an “in-house” specialty pharmacy improves care – as one URMC study showed slightly higher adherence (^[12]). These IHSSPs allow clinics to manage a broader portfolio of drugs and to track patients more easily, supporting the notion that clustering specialty care under one roof can yield process improvements.

Specialty Pharmacy Management Programs (Payers)

Many insurers run preferred specialty networks or management programs. For example, some Medicaid programs mandate that certain drugs be obtained only through state-contracted specialty pharmacies. Commercial plans might require step therapy, split-fill, or biological product substitution. These programs often restrict which pharmacies can dispense, purportedly to reduce waste (e.g. if a patient doesn’t tolerate a drug, minimize leftover inventory). Sometimes they direct patients to one specialty provider to track utilization.

A case in point is the Integrated Care Pathway for Hepatitis C, where some states or health plans ensure patients fill HCV antivirals only through preferred specialty pharmacies that offer case management and subsidy programs. Results in such programs include higher rates of treatment completion and cure than in fee-for-service models.

Specialty Pharmacy in the Post-Pandemic Era

The COVID-19 pandemic brought specialty pharmacy into new domains (e.g. monoclonal antibody treatments distributed via infusion centers) and accelerated mail-order and telepharmacy adoption. In the post-pandemic landscape, specialty pharmacy has pivoted to its expanding core mission: managing the surge of GLP-1 weight-loss and diabetes drugs (a $53.5 billion market in 2024), navigating the growing pipeline of gene and cell therapies (over 22 FDA-approved as of 2025, with costs exceeding $3.5 million per treatment for some), and adapting to the IRA’s landmark Medicare drug pricing reforms. The cold-chain logistics expertise developed during vaccine rollouts continues to be essential for biologics and gene therapies.

In summary, practical deployments of specialty pharmacy run the gamut from startup ventures to giant chain strategies. The common thread is enhancing access and adherence for complex therapies, often by re-engineering the usual pharmacy workflow.

Policy, Regulation, and Reimbursement

Specialty pharmacy operates under a complex policy environment. In the U.S., there is no single legal definition of “specialty pharmacy” in statute; rather, definitions come from industry groups and program rules. For example, Medicare Part D historically defined a “specialty drug” as one above a certain price threshold (recently ~$670 per month) that requires special handling, and plans can charge higher coinsurance on such drugs. NASP’s definitions (as noted above) are widely cited by Congress and CMS when crafting benefit rules (^[47]) (^[5]). In 2016, NASP formally defined specialty drugs as those for complex chronic conditions requiring special patient care services (^[47]).

Regulatory bodies have significantly escalated their scrutiny of specialty pharmacy practices. The FTC filed suit against all three major PBMs for anticompetitive insulin rebating practices, and in February 2026 secured a landmark settlement with Express Scripts requiring elimination of spread pricing, delinking PBM compensation from drug list prices, and reshoring its group purchasing organization to the U.S. (^[16]). Cases against CVS Caremark and OptumRx remain pending. State attorneys general have also investigated PBM practices, and lawmakers have considered mandating bonds or financial solvency requirements for specialty pharmacies after some went bankrupt and left patients in limbo. Additionally, because specialty therapy coverage consumes large insurer budgets, state regulators increasingly require that health plans have clear processes for specialty drug tiers and that they offer exceptions or alternatives.

Medicare Part D’s benefit structure has historically posed challenges for specialty drug patients. Part D plans categorize drugs into tiers; specialty drugs often fall in tier 4 or 5 with coinsurance (e.g. 25–33%). The Inflation Reduction Act (IRA) has now significantly reshaped Part D: as of January 1, 2025, all Part D enrollees benefit from a $2,000 annual out-of-pocket cap on prescription drug costs (including deductibles, copays, and coinsurance), with approximately 11 million enrollees expected to benefit and average savings of ~$600 per year (^[45]). For 2026, this cap was inflation-adjusted to $2,100. The IRA also introduced Medicare drug price negotiations: negotiated Maximum Fair Prices for the first 10 Part D drugs took effect January 2026, and 15 additional drugs have been selected for 2027 pricing (^[46]). These represent landmark changes for specialty drug patients, though specialty pharmacies continue to play a vital role in navigating coverage, co-pay assistance, and manufacturer patient assistance programs.

At the state level, specialty pharmacy is often in the policy crosshairs of PBM regulation. Many states have passed “pharmacy benefit manager” laws aiming for transparency in rebates, prohibiting spread pricing, and ensuring independent pharmacies (including specialty) are reimbursed fairly. These changes can indirectly affect specialty pharmacy economics.

In terms of accreditation, specialty pharmacies must meet stringent standards. Organizations like URAC or the CPPA (Center for Pharmacy Practice Accreditation) offer specialty-specific accreditations that cover things like staff training, metrics reporting, and patient education programs. URAC released Version 5.0 of its specialty pharmacy accreditation standards, which reduced the accreditation timeline by six months and introduced a "Small Pharmacy" accreditation for smaller and startup specialty pharmacies. ACHC also updated its standards in early 2025, including changes to DMEPOS requirements within specialty pharmacy. Maintaining such accreditation (and HIPAA and DEA compliance due to controlled substances in some cases) is key for pharmacies to contract with payers and manufacturers.

Challenges, Controversies, and Dual Perspectives

Specialty pharmacy has its critics. Some patient advocates argue that the fragmentation of distribution (e.g. LDNs) sometimes blocks patients from getting the nearest competent service, and that co-pay assistance may hide true costs. Insurers lament that specialty therapeutics often provide comfortable profit for manufacturers even when cheaper alternatives exist, and they accuse some specialty pharmacies (especially in-house PBM-owned ones) of lacking price competition. Community pharmacists sometimes see specialty pharmacies as siphoning off business: if a patient’s asthma or cholesterol pills are filled retail, but their new rheumatoid arthritis biologic must go to mail-order, the local pharmacist loses that touchpoint with the patient. The consolidation of retail chains into specialty means fewer independent pharmacy options for consumers.

Research also highlights operational challenges: surveys of pharmacists indicate that working conditions in specialty pharmacies can be high-pressure, with quotas for throughput and complex troubleshooting burdens. The booming business can also mean that smaller pharmacies struggle to handle the working capital required to stock expensive inventory (a single bottle of specialty biologic may cost tens of thousands).

On the other hand, supporters argue that specialty pharmacy restores care that otherwise retail pharmacists, pharmacy technicians or unaffiliated outlets cannot provide at scale. In particular, specialty pharmacists undergo additional training in disease management (some are board-certified specialists). The industry often cites studies on improved adherence and outcomes (as noted above) to justify its existence. Many physicians specializing in complex diseases welcome specialty pharmacy as a partner (as long as there is communication). Payers, while frustrated by costs, recognize that without specialty pharmacy case management they might face far higher medical costs from uncontrolled disease.

Future Directions and Innovations

The future of specialty pharmacy is tied to the trajectory of pharmaceutical innovation. Gene and cell therapies have moved from emerging to established: over 22 FDA-approved cell and gene therapies are now on the market as of 2025, with projections of 200+ approvals and 100,000 treated patients in the U.S. by 2030 (^[48]). The most expensive gene therapies cost over $3.5 million per treatment, with total gene therapy spending projected at $25.3 billion in 2026 (^[49]). Starting in 2025, state Medicaid programs can participate in the CMS Cell and Gene Therapy Access Model with outcomes-based agreements, creating new reimbursement pathways. Specialty pharmacy is evolving to manage “pre and post” care for these therapies: ordering extremely high-cost treatments and monitoring patients for rare but serious long-term effects.

Digital health and analytics continue to shape specialty care. Customer (patient) portals, mobile apps, and automated refill reminders are already part of some specialty pharmacy programs. AI-driven adherence predictions could target interventions (e.g. identify patients at 30% treatment completion and intervene). Telepharmacy (pharmacist visits via video) can extend specialty services to remote patients, especially for training on injectable meds.

The GLP-1 revolution is reshaping specialty pharmacy economics. With the GLP-1 market estimated at $53.5 billion in 2024 and projected to reach $156.7 billion by 2030, these drugs have become a transformative force in drug spending (^[50]). A November 2025 deal between the White House and manufacturers brought injectable GLP-1 prices down to ~$350/month (from $1,000+), with commitments to reach ~$250/month within two years and Medicare beneficiary costs of $50/month (^[51]). Specialty pharmacies are central to managing access, adherence, and cost navigation for these therapies.

Another trend is patient-centric networks and new benefit models. Some employers are experimenting with employer-owned PBMs or direct contracting with biotech companies, especially for high-cost drugs. Specialty pharmacies may have to adapt to value-based arrangements: for example, a plan might only reimburse fully if the specialty drug achieves its intended outcome. This could favor specialty programs that track outcomes rigorously. The FTC's February 2026 settlement with Express Scripts — requiring elimination of spread pricing and delinking of compensation from list prices — signals a broader regulatory shift that could reshape specialty channel economics for all PBMs.

Regulatory changes are no longer just on the horizon — they are here. The IRA's Medicare drug price negotiations (10 drugs in 2026, 15 more in 2027) and the $2,000 out-of-pocket cap are already reshaping specialty pharmacy economics. Additional legislation to increase drug pricing transparency or importation could further impact the field. Conversely, if rules require more dispensing through retail or through 340B entities, specialty mail-order models might need adjustment.

Globally, other countries’ approaches differ: in many countries with single-payer systems, specialty drugs are handled by hospital pharmacies or centralized distributors. Lessons from abroad (like government-run specialty clinics) may influence U.S. practice.

Finally, patient expectations are rising. As healthcare becomes more consumer-focused, patients demand more convenience (same-day home delivery, multilingual support, financial navigation). Specialty pharmacies that innovate (e.g. rapid courier service for fragile biologics, extended hours hotlines) will stand out. Large digital players are increasingly entering specialty pharmacy: Amazon Pharmacy is expanding same-day delivery to nearly 4,500 U.S. cities by end of 2026, while Mark Cuban’s Cost Plus Drugs has moved aggressively into specialty medications and biosimilars, building compounding facilities and partnering directly with PBMs and employers to bypass traditional pricing structures (^[52]). These developments indicate an accelerating blurring of lines between traditional specialty pharmacy, digital health, and direct-to-consumer models.

Tables

Table 3: Key differences between retail vs specialty pharmacy (additional to Table 2, citing industry definitions and analyses (^[17]) (^[25])).

Table 4: Core operational characteristics of specialty pharmacies (derived from NASP definitions, industry reports, and case analyses (^[5])).

Conclusion

Specialty pharmacy is a rapidly expanding segment of healthcare defined by its focus on complex, high-cost therapies and intensive patient support services. It has transformed how certain medications reach patients and how chronic, serious diseases are managed in the community. By concentrating expertise, technology, and continuity of care around these medications, specialty pharmacies have demonstrated the ability to improve adherence and clinical outcomes for conditions like multiple sclerosis (^[30]) and hepatitis C (^[11]). However, this specialization comes at a high financial cost that has reshaped drug economics: specialty drugs now account for 54% of total U.S. drug spending as of 2024 (^[6]), spurring policies to manage utilization and control price inflation.

Going forward, specialty pharmacy will continue to adapt to innovations — with over 22 FDA-approved gene and cell therapies now on the market and projections of 200+ by 2030 — and to the evolving healthcare payment landscape. The IRA’s Medicare drug price negotiations (10 drugs in 2026, 15 more in 2027) and the $2,000 out-of-pocket cap are already reshaping the economics. The FTC’s landmark 2026 settlement with Express Scripts, requiring elimination of spread pricing, signals structural change in PBM practices. Emerging models that integrate specialty pharmacists with care teams (as in physician clinic sites) offer promising ways to reduce patient burden and improve outcomes. Meanwhile, regulators and payers are scrutinizing the specialty channel’s role in drug costs and access, from the structure of PBM rebates to the fairness of limited distribution practices (^[15]).

As the specialty pharmacy field matures, the key challenge will be to sustain its benefits (enhanced patient care, focused expertise) while addressing cost and access concerns. Already, specialty pharmacies are tracking outcomes and pursuing value-based contracts to demonstrate return on investment in terms of avoided hospitalizations and improved population health. In sum, specialty pharmacy will remain a crucial interface between patients and next-generation therapies, and its evolution will mirror broader trends in personalized, high-tech medicine.

References: All statements and data above are supported by industry analyses, peer-reviewed studies, and credible news and regulatory sources (^[5]) (^[2]) (^[21]) (^[30]) (^[11]) (^[6]) (^[16]) (see inline citations).